J&J's pill approval is a game changer

Cramer breaks down J&J FDA approval for an oral IL-23 antagonist and its market implications versus injectables.

Play episode from 20:37

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!